Loading…

Sweet syndrome: long-term follow-up of 138 patients

Summary Background Several studies support a strong association of Sweet syndrome (SS) with malignancy. However, only a few studies analysing the clinical features of malignancy‐associated SS have been published in recent years. Aim To retrospectively study the clinical features of SS that could pre...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental dermatology 2016-10, Vol.41 (7), p.741-746
Main Authors: Marcoval, J., Martín-Callizo, C., Valentí-Medina, F., Bonfill-Ortí, M., Martínez-Molina, L.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Background Several studies support a strong association of Sweet syndrome (SS) with malignancy. However, only a few studies analysing the clinical features of malignancy‐associated SS have been published in recent years. Aim To retrospectively study the clinical features of SS that could predict the development of associated malignancies and to analyse the development of malignant neoplasia during long‐term follow‐up of patients with SS. Methods Clinical features of the patients diagnosed with SS syndrome between 1987 and 2013 at Bellvitge Hospital (Barcelona, Spain) were retrospectively analysed. Results In total, 138 patients were included in the study (66 male, 72 female, mean ± SD age 51.24 ± 14.11 years). SS was associated with haematological malignancy in 31 cases, infection in 23, inflammatory bowel disease in 12, inflammatory systemic disease in 8, and solid tumours in 4. It was drug‐induced in 5 cases and idiopathic in 54. In four patients, an underlying haematological disease that was considered related to SS was diagnosed between 4 and 16 months after SS presentation. Variables significantly associated with malignancy in multivariate logistic regression analysis were age (OR = 1.08 for each increasing year, P = 0.01), anaemia (OR = 9.38, P = 0.001), thrombocytopenia (OR = 16.10, P 
ISSN:0307-6938
1365-2230
DOI:10.1111/ced.12899